MNKD
MannKind Corporation NASDAQ Listed Jul 28, 2004$3.94
+0.51%
vs $3.92
Mkt Cap $1.2B
52w Low $2.28
42.2% of range
52w High $6.21
50d MA $3.21
200d MA $4.53
P/E (TTM)
197.0x
EV/EBITDA
50.4x
P/B
—
Debt/Equity
-9.3x
ROE
-11.5%
P/FCF
90.4x
RSI (14)
55.00
ATR (14)
$0.22
Beta
1.04
50d MA
$3.21
200d MA
$4.53
Avg Volume
6.1M
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
30930 Russell Ranch Road · Danbury, CA 91362 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.02 | -0.05 | -150.0% | 3.56 | -6.7% | -0.3% | -0.8% | -4.5% | -2.4% | -2.1% | — |
| Feb 26, 2026 | AMC | -0.01 | -0.05 | -400.0% | 3.24 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% | — |
| Nov 5, 2025 | AMC | 0.01 | 0.03 | +200.0% | 6.06 | +1.2% | -5.9% | -1.2% | -3.7% | -3.1% | +0.0% | — |
| Aug 6, 2025 | AMC | 0.04 | 0.00 | -94.8% | 3.47 | +2.9% | -1.2% | +2.6% | -2.8% | +7.0% | +1.9% | — |
| May 8, 2025 | AMC | 0.03 | 0.04 | +33.3% | 4.63 | +0.2% | -1.5% | +5.5% | -1.9% | -3.2% | -0.2% | — |
| Feb 26, 2025 | AMC | 0.03 | 0.03 | +0.0% | 5.47 | +0.0% | -4.4% | +2.1% | -3.9% | +0.4% | +0.0% | — |
| Nov 7, 2024 | AMC | 0.06 | 0.04 | -33.3% | 7.39 | -5.4% | -0.5% | -1.8% | -1.9% | -1.7% | +0.9% | — |
| Aug 7, 2024 | AMC | -0.03 | 0.05 | +250.1% | 5.01 | +2.0% | +3.6% | -2.7% | +2.8% | -2.3% | +2.4% | — |
| May 8, 2024 | AMC | 0.03 | 0.04 | +53.8% | 4.40 | +3.4% | -2.0% | +0.2% | +2.1% | +2.0% | -1.1% | — |
| Feb 27, 2024 | AMC | — | 0.02 | — | 3.78 | +3.2% | +3.7% | +4.8% | +9.5% | +3.3% | +2.2% | — |
| Nov 7, 2023 | AMC | 0.01 | 0.02 | +160.4% | 3.80 | +5.8% | -3.9% | -4.9% | -1.2% | +3.2% | +5.1% | — |
| Aug 7, 2023 | AMC | -0.01 | -0.02 | -47.2% | 4.60 | +8.7% | +18.5% | -2.0% | -0.9% | -0.8% | +0.4% | — |
| May 9, 2023 | AMC | -0.05 | -0.04 | +20.0% | 3.80 | +5.8% | +15.8% | -3.6% | -0.2% | +7.1% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.63 | $2.67 | +1.5% | +6.1% | -1.4% | +2.9% | +0.4% | -1.1% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $2.57 | $2.57 | +0.0% | +2.7% | +3.8% | +1.1% | -0.7% | +3.3% |
| Mar 5 | Wedbush | Maintains | Outperform → Outperform | — | $2.95 | $2.94 | -0.3% | -4.1% | -7.8% | +2.7% | -2.6% | +8.0% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 27 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.24 | $3.15 | -2.8% | +1.2% | -7.3% | -3.6% | +0.7% | -4.1% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.54 | $5.54 | +0.0% | -36.8% | -7.4% | +1.2% | -7.3% | -3.6% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.46 | $5.47 | +0.2% | +2.2% | +0.2% | +0.9% | +2.7% | -0.2% |
| Nov 11 | RBC Capital | Maintains | Outperform → Outperform | — | $5.42 | $5.34 | -1.5% | -3.1% | +0.0% | -3.4% | -0.2% | -1.6% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.42 | $5.34 | -1.5% | -3.1% | +0.0% | -3.4% | -0.2% | -1.6% |
| Oct 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.92 | +0.8% | +4.5% | +0.0% | +2.5% | +2.3% | +2.2% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $5.40 | +0.2% | +4.1% | -3.2% | +2.6% | -3.9% | -0.4% |
| Sep 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.34 | $5.48 | +2.6% | +3.7% | +0.5% | -1.1% | +1.1% | -2.7% |
| Sep 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.74 | $5.74 | +0.0% | -4.0% | -3.1% | +3.7% | +0.5% | -1.1% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.59 | $6.06 | +32.0% | +25.1% | -4.0% | -3.1% | +3.7% | +0.5% |
| Aug 26 | RBC Capital | Maintains | Outperform → Outperform | — | $3.90 | $4.12 | +5.6% | +4.4% | +11.1% | -0.7% | +2.2% | +25.1% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $3.47 | $3.57 | +2.9% | -1.2% | +2.6% | -2.8% | +7.0% | +1.9% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.08 | $4.10 | +0.5% | -0.5% | -2.5% | -3.5% | +1.3% | -2.3% |
| Jul 23 | RBC Capital | Maintains | Outperform → Outperform | — | $3.93 | $3.93 | +0.0% | +4.3% | -0.5% | -0.5% | -2.5% | -3.5% |
| Dec 19 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $5.94 | $6.30 | +6.1% | +6.1% | +8.7% | +2.5% | -4.0% | +2.2% |
| Aug 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.38 | $5.46 | +1.5% | +9.7% | +7.3% | -1.1% | -2.9% | +0.2% |
| May 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.40 | $4.55 | +3.4% | -2.0% | +0.2% | +2.1% | +2.0% | -1.1% |
| Mar 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.50 | $4.46 | -0.9% | -0.7% | +3.4% | +1.1% | +3.2% | -1.2% |
| Feb 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.78 | $3.90 | +3.2% | +3.7% | +4.8% | +9.5% | +3.3% | +2.2% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.74 | +1.1% | +3.2% | -4.7% | +1.9% | -3.8% | +0.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.29 | +0.8% | +0.4% | -0.6% | -3.6% | -2.0% | +0.6% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.60 | $5.00 | +8.7% | +18.5% | -2.0% | -0.9% | -0.8% | +0.4% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.42 | +0.5% | -3.6% | -0.2% | +7.1% | -3.1% | +3.6% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.41 | $5.55 | +2.6% | -0.6% | -1.9% | -8.5% | -0.4% | +1.2% |
| Nov 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.81 | $3.82 | +0.3% | +1.3% | +10.1% | +3.1% | -2.7% | +3.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.65 | -2.6% | -3.7% | +5.0% | +17.8% | -3.4% | -4.2% |
| Mar 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.38 | $3.49 | +3.3% | +8.6% | -1.1% | +4.7% | +1.3% | +2.6% |
| Mar 1 | Maxim Group | Downgrade | Hold → Sell | — | $2.93 | $2.84 | -3.1% | -3.1% | -0.4% | +0.4% | -1.1% | -1.4% |
| Nov 1 | Maxim Group | Downgrade | Buy → Hold | — | $3.29 | $3.28 | -0.3% | -8.5% | +7.3% | +0.9% | -0.9% | +0.6% |
| Nov 16 | Griffin Securities | Downgrade | Buy → Neutral | — | $12.20 | $11.45 | -6.1% | -7.4% | +0.0% | +3.1% | +3.4% | +2.5% |
| Nov 4 | RBC Capital | Downgrade | Outperform → Underperform | — | $16.15 | $15.25 | -5.6% | -7.4% | -6.7% | +2.9% | -8.4% | -12.5% |
| Sep 9 | Piper Sandler | Downgrade | Neutral → Underweight | — | $20.35 | $18.60 | -8.6% | -10.1% | +2.5% | -1.3% | -3.5% | +0.8% |
| May 11 | JP Morgan | Downgrade | Neutral → Underweight | — | $19.05 | $18.25 | -4.2% | -4.7% | +0.6% | -0.5% | +0.0% | +10.1% |
| Mar 3 | Goldman Sachs | Downgrade | Neutral → Sell | — | $33.20 | $30.60 | -7.8% | -7.2% | -3.6% | -3.5% | -4.5% | -2.4% |
| Jul 1 | MLV & Co. | Downgrade | Buy → Hold | — | $54.80 | $54.00 | -1.5% | -5.8% | -4.3% | +1.2% | -0.9% | -2.2% |
| May 14 | Piper Sandler | Upgrade | Underweight → Neutral | — | $32.90 | $33.30 | +1.2% | +6.5% | -1.1% | +1.3% | +5.3% | +2.4% |
| Apr 2 | McNicoll Lewis Vlak | Maintains | Buy → Buy | — | $21.00 | $38.75 | +84.5% | +66.4% | -0.9% | -0.9% | -8.0% | +3.5% |
| Mar 31 | Piper Sandler | Downgrade | Neutral → Underweight | — | $24.15 | $22.20 | -8.1% | -16.8% | +4.5% | +66.4% | -0.9% | -0.9% |
| Sep 6 | BofA Securities | Downgrade | Neutral → Underperform | — | $31.50 | $30.00 | -4.8% | -7.0% | +2.0% | +1.2% | -2.8% | -0.3% |
| Jun 7 | BofA Securities | Downgrade | Buy → Neutral | — | $38.25 | $37.30 | -2.5% | -2.5% | +0.5% | +2.0% | -0.1% | -2.2% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $16.65 | $17.15 | +3.0% | +1.2% | +0.6% | +4.4% | +7.1% | -0.8% |
| Nov 8 | Imperial Capital | Maintains | Outperform → Outperform | — | $9.80 | $9.70 | -1.0% | -1.5% | +2.6% | +0.0% | -1.0% | -2.8% |
| Nov 5 | BofA Securities | Upgrade | Neutral → Buy | — | $9.90 | $10.25 | +3.5% | +2.0% | +0.5% | -3.4% | -1.5% | +2.6% |
| Nov 2 | JP Morgan | Upgrade | Underweight → Neutral | — | $9.64 | $9.95 | +3.2% | +2.7% | +2.0% | +0.5% | -3.4% | -1.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | Thomson David | EVP Genl Counsel & Secretary | Sell | 3,033 | $3.29 | $10K | 826,299 | +0.31% | +9.80% |
| May 12, 2026 | Binder Steven B. | — | Sell | 16,940 | $3.29 | $56K | 808,008 | +0.31% | +9.80% |
8-K · 8.01
!! High
MannKind Corporation -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
MannKind Corporation -- 8-K 8.01: Material Event / Announcement
May 28
8-K · 2.02
!! High
Pulmatrix, Inc. -- 8-K 2.02: Earnings Results
May 15
8-K
Mannkind Corporation -- 8-K Filing
MannKind's Furoscix ReadyFlow Autoinjector will receive FDA review completion by July 26, 2026, potentially expanding its commercial portfolio and supporting future revenue growth if approved.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 8,887,844 | $50M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 12,891,066 | $32M | New | Mar 2026 |
| 3 | Ubs Group Ag | 8,255,430 | $20M | Added | Mar 2026 |
| 4 | Millennium Management | 6,390,922 | $16M | Added | Mar 2026 |
| 5 | 180 Wealth Advisors, Llc | 4,291,703 | $11M | Added | Mar 2026 |
| 6 | Fmr Llc | 3,480,964 | $9M | Reduced | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 3,383,677 | $8M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 3,171,824 | $8M | New | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 2,895,874 | $7M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 2,675,950 | $7M | Added | Mar 2026 |
| 11 | Deltec Asset Management Llc | 974,700 | $6M | Added | Dec 2025 |
| 12 | Avoro Capital Advisors Llc | 2,200,000 | $5M | Reduced | Mar 2026 |
| 13 | Nuveen, Llc | 2,164,715 | $5M | — | Mar 2026 |
| 14 | Qube Research & Technologies Ltd | 2,149,393 | $5M | Added | Mar 2026 |
| 15 | Renaissance Technologies Llc | 1,868,442 | $5M | Added | Mar 2026 |
| 16 | Marshall Wace, Llp | 1,561,889 | $4M | Added | Mar 2026 |
| 17 | Invesco Ltd. | 1,505,604 | $4M | Reduced | Mar 2026 |
| 18 | Jane Street Group, Llc | 548,257 | $3M | Added | Dec 2025 |
| 19 | Point72 Asset Management | 1,249,177 | $3M | New | Mar 2026 |
| 20 | Victory Capital Management Inc | 1,232,078 | $3M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.24B
Enterprise Value
$1.39B
P/E (TTM)
197.00x
Forward P/E
241.72x
PEG Ratio
-3.69x
P/B
—
P/S
3.55x
P/FCF
90.41x
EV/EBITDA
50.38x
Shares Out
314.1M
Financials (TTM)
Revenue
$349.0M
Net Income
$5.9M
EBITDA
$27.5M
Free Cash Flow
$13.7M
Op Cash Flow
$18.3M
EPS Basic
$0.02
EPS Diluted
$0.02
EPS Forward
$0.02
Gross Margin
82.5%
Op Margin
11.1%
Net Margin
1.7%
Balance Sheet
Total Assets
$792.2M
Total Liab.
$843.2M
Total Equity
-$51.0M
Cash
$171.3M
LT Debt
$320.4M
Book Value/Sh
$-0.17
Debt/Equity
-9.28x
Current Ratio
1.70
Quick Ratio
1.50
Returns & Growth
ROE
-11.5%
ROA
0.7%
ROIC
5.8%
Rev Growth YoY
+22.2%
EPS Growth YoY
-80.0%
Price Returns
2W
+17.1%
1M
+33.2%
3M
+14.9%
6M
-29.5%
12M
-9.2%
Technicals
52W High
$6.21
52W Low
$2.28
50d MA
$3.21
200d MA
$4.53
RSI (14)
55.00
ATR (14)
$0.22
Beta
1.04
Avg Volume
6.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$8.00
Low
$6.00
Median
$7.00
Data updated apr 26, 2026 12:47pm
· Source: financialmodelingprep.com